Source: Eur Respir J 2015; 45: 1393-1402
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Wilkes David S., Chew Terrence, Flaherty Kevin R., Frye Sarah, Gibson Kevin F., Kaminski Naftali, Klemsz Michael J., Lange Wade, Noth Imre, Rothhaar Katia. Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1393-1402

Member's Comments

No comment yet.

Related content which might interest you: Collagen V nasal tolerance promotes decrease in topoisomerase-1 and pulmonary fibrosis of systemic sclerosis model Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Collagen V and decorin is involved in systemic sclerosis pulmonary fibrosis Source: Annual Congress 2011 - The ageing pulmonary interstitium Year: 2011 Systemic sclerosis patients‘ sera recognize collagen V in experimental scleroderma lung fibrosis Source: Annual Congress 2011 - The ageing pulmonary interstitium Year: 2011 Serum type III procollagen peptide in idiopathic pulmonary fibrosis: peptide levels and anti-fibrosis therapy Source: Eur Respir J 2005; 26: Suppl. 49, 30s Year: 2005 Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 342s Year: 2002 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Effect of nintedanib on hyaluronic acid metabolism in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Abnormal collagen type V deposition in lung fibroblast is correlated with a worse pulmonary function in systemic sclerosis Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases Year: 2007 Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019 Year: 2019 Late stage of experimental pulmonary fibrosis is modulated by collagen V Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Serum levels of a MMP-12 generated type IV collagen fragment is elevated in COPD and IPF patients Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Assessment of collagen in human idiopathic pulmonary fibrosis using second harmonics on Genesis 200 Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias Year: 2018 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Type V collagen nasal tolerance regulates collagen mRNA synthesis in pulmonary remodeling of experimental systemic sclerosis Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Differential metabolism of hyaluronic acid in patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015